Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

revenues were due to payments received in previous years from NicOx' partnered programs with Merck & Co., Inc. in the antihypertensive field and Pfizer Inc in ophthalmology.

Operating expenses totaled EUR86.4 million in 2008, compared to EUR61.8 million in 2007. The majority of these expenses were associated with the phase 3 clinical program for naproxcinod in osteoarthritis (OA) patients, which was successfully completed in the second half of 2008. Naproxcinod is the first Cyclooxygenase-Inhibiting Nitric Oxide Donator (CINOD) and a New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) is projected for mid-2009. NicOx' net loss was EUR73.9 million for the full year 2008, compared to EUR32.1 million in 2007.

On December 31, 2008, NicOx had cash, cash equivalents and financial instruments of EUR104.7 million, compared to EUR172.8 million on December 31, 2007.

Considerable progress made in naproxcinod pre-commercialization activities

In 2008, NicOx signed two major manufacturing agreements to prepare the commercial launch of naproxcinod. In September, an agreement was signed with Capsugel, for the commercial manufacture and supply of naproxcinod capsules and in December, an agreement was signed with DSM for the commercial manufacturing and supply of naproxcinod drug substance (Active Pharmaceutical Ingredient, API). The aim of these agreements is to ensure sufficient commercial supplies of naproxcinod to underpin its successful market launch.

NicOx is currently in discussions with a number of companies regarding a potential commercialization agreement for naproxcinod. NicOx aims to retain certain commercialization rights for naproxcinod, in order to fully exploit the drug's commercial and strategic value and aid the Company's planned transition to a self-sustainable pharmaceutical business.

Completed phase 3 program confirms naprox
'/>"/>

SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 Tobira Therapeutics, Inc. (NASDAQ: ... development and commercialization of novel treatments for liver ... its merger with Regado Biosciences, Inc. (NASDAQ: RGDO, ... of the merger, Tobira raised $40 million of ... and all current Tobira institutional investors, including the ...
(Date:5/4/2015)... Tenn. , May 4, 2015   ... developed a significantly better computer tool for finding ... many cancers but were difficult to identify with ... scientific journal Nature Methods . ... for Copy Number Segmentation by Regression Tree in ...
(Date:5/4/2015)... May 4, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on Form 20-F for the fiscal year ended December ... ("SEC"). The annual report on Form 20-F contains information ... in the area of cancer immune checkpoints. This project ... high specificity and binding in targeting certain identified immune ...
(Date:5/4/2015)... 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), a FACIT ... of Dr. Roger J Garceau, to its Board ... in matters including corporate development and clinical strategy, ... significant regulatory expertise as Fluorinov transitions to clinical ... years of pharmaceutical development experience to Fluorinov and ...
Breaking Biology Technology:Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3
... clinicians identify best treatment ... risk of heart disease, BIRMINGHAM, Ala., March 7 ... its VAP,Cholesterol Test(R) in Booth 21041 at the American College ... takes,place March 29-April 1, 2008, at the McCormick Place Convention ...
... ABT ),will present at the Cowen and Company ... Thomas C. Freyman, executive vice president,finance and chief financial ... 10:30 a.m. Central time., A live audio webcast ... Web site at http://www.abbottinvestor.com . An,archived edition of ...
... 7 Finesse Solutions, LLC, a,manufacturer of measurement ... Nova Biomedical, Waltham, MA, a world leader in,biotechnology ... OPC connectivity between TruBio(TM) OS and Nova BioProfile ... Both companies confirmed that a,TruBio(TM) OS plug-in for ...
Cached Biology Technology:Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago 2Finesse Solutions, LLC Announces OPC Connectivity With Nova BioProfile 400 2
(Date:4/2/2015)... , April 2, 2015 At its ... Salt Lake City , the American College of ... five new directors to its Board.  Members of the ... ACMG and for forming and advancing its policies and ... genetics profession. "It,s an eventful time in ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... Dyck has been unearthing some intriguing facts related to ... Canada in the '50s and '60s. , Among ... professor has found records of the psychiatrists' research that ... provided in a clinical, nurturing environment, can be an ...
... mammals use their whiskers to explore their environment and ... for example, use their whiskers to determine the size, ... whiskers to track the fluid wakes of their prey. ... the whisker system of rats to better understand how ...
... With wheat stem sawfly natural enemies in demand, ... increasing their availability. , This fall, the ... mass-rearing parasitic wasps that attack wheat stem sawfly ... plants. The team includes entomologists David Weaver, master's ...
Cached Biology News:LSD treatment for alcoholism gets new look 2LSD treatment for alcoholism gets new look 3Robotic whiskers can sense three-dimensional environment 2Rearing an army to save wheat 2Rearing an army to save wheat 3
BDFastImmune? IFN-gamma /CD69/CD4/CD3 Storage Temperature: Refrigerate(2 to 8C)...
MAb to Transferrin Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Rabbit polyclonal to Phosphothreonine-X-Phosphotyrosine (HRP) ( Abpromise for all tested applications)....
Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
Biology Products: